Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly

Background. Pharmacoeconomic aspects of somatostatin analogues remain an important topic for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage in terms of administration convenience and high efficacy.

Objective: to carry out a cost-effectiveness analysis (CEA) of the use of lanreotide and prolonged-release octreotide in adult patients with acromegaly.

Material and methods. A cost model for the treatment of acromegaly patients during the period of 2.5 years was developed, accounting for direct medical costs for drugs and surgical intervention. A pharmacoeconomic study by the CEA method and a sensitivity analysis of the model were performed.

Results. In real clinical practice of acromegaly treatment, lanreotide enables a more effective remission compared to prolonged-release octreotide (51% vs 24%) under a comparable safety profile. The direct medical costs for a 2.5-year course of lanreotide amounted to 1,466,669.49 rubles per patient with acromegaly compared to 908,272.53 rubles for a course of prolonged-release octreotide. Considering the difference in the amount of 558,096.79 rubles, the course of lanreotide was found to be 25% more expensive. According to CEA results, the cost of achieving remission in 1 patient with acromegaly with lanreotide and prolonged-release octreotide was equal to 2,415,036.25 and 3,676,115.43 rubles, respectively. Therefore, over the period of 2.5 years, the cost saving amounted to 1,261,079.17 rubles (52%). The sensitivity analysis demonstrated the robustness of the initial model against an increase in the price of lanreotide up to 64%, an increase in the frequency of surgery in patients receiving lanreotide up to 302%, and a decrease in the frequency of remissions in patients receiving lanreotide up to 35%.

Conclusion. The use of lanreotide in adult patients with acromegaly is a clinically and cost-effective approach in the context of the Russian healthcare system.

1. Antsiferov M.B., Petryaikin A.V., Alekseeva T.M., et al. Modern possibilities of tumor-oriented diagnostics and treatment of acromegaly. Farmateka. 2023; 30 (3): 78–89 (in Russ.). https://doi.org/10.18565/pharmateca.2023.3.78-88.

2. Crisafulli S., Luxi N., Sultana J., et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021; 185 (2): 251–63. https://doi.org/10.1530/EJE-21-0216.

3. Lutsenko A.S., Przhiyalkovskaya E.G., Vikulova O.K., et al. Acromegaly: clinical and epidemiological data of the all-Russian registry of tumors of the hypothalamic-pituitary region. Мoscow: Tipografiya “Pechatnykh del master”; 2024: 40 pp. (in Russ.).

4. Przhiyalkovskaya E.G., Mokrysheva N.G., Troshina E.A., et al. Guidelines on diagnostics and treatment of acromegaly (draft). Obesity and Metabolism. 2024; 21 (2): 215–49 (in Russ.). https://doi.org/10.14341/omet13153.

5. Cella D., Evans J., Feuilly M., et al. Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. Adv Ther. 2021; 38 (2): 969–93. https://doi.org/10.1007/s12325-020-01600-x.

6. Dzeranova L.K., Yevloyeva M.I., Perepelova M.A., et al. Efficacy of longterm octreotide therapy of acromegaly as the first-line medical treatment. Obesity and Metabolism. 2023; 20 (1): 66–72 (in Russ.). https://doi.org/10.14341/omet12960.

7. Kerbel J., Cano-Zaragoza A., Espinosa-Dorado R., et al. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: a registries-based approach. Arch Med Res. 2023; 54 (6): 102856. https://doi.org/10.1016/j.arcmed.2023.102856.

8. Auriemma R.S., Pivonello R., Galdiero M., et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest. 2008; 31 (11): 956–65. https://doi.org/10.1007/BF03345632.

9. Chanson P., Boerlin V., Ajzenberg C., et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol. 2000; 53 (5): 577–86. https://doi.org/10.1046/j.1365-2265.2000.01134.x.

10. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metabol. 2010; 95 (7): 3141–8. https://doi.org/10.1210/jc.2009-2670.

11. Pronin V.S., Antsiferov M.B., Alexeeva T.M., Pronin E.V. Targeted treatment with somatostatin analogues: widening horizons of clinical practice. Almanac of Clinical Medicine. 2022; 50 (3): 196–204 (in Russ.). https://doi.org/10.18786/2072-0505-2022-50-019.

12. Somatuline® Autogel®. Product monograph. Available at: https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/sites/16/2024/08/20081226/PM-Somatuline-Autogel-EN-8Aug2023.pdf (accessed 15.01.2025).

13. Ronchi C.L., Boschetti M., Degli Uberti E.C., et al. Efficacy of a slowrelease formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol. 2007; 67 (4): 512–9. https://doi.org/10.1111/j.1365-2265.2007.02917.x.

14. European Medicines Agency. Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product6 specific bioequivalence guidance. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-lanreotide-acetate-prolongedrelease-solution-injection-prefilled-syringe-60-90-and-120-mg-productspecific-bioequivalence-guidance_en.pdf (accessed 15.01.2025)

15. Kim S. young, Kim D. Comparison of the efficacy of octreotide longacting repeatable and lanreotide autogel in acromegalic patients. Endocrinol Metab. 2010; 25 (1): 37–45. https://doi.org/10.3803/jkes.2010.25.1.37.

16. Belaya Zh.E., Golounina O.O., Rozhinskaya L.Y., et al. Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the United Russian Registry of Patients with Pituitary Tumors. Problems of Endocrinology. 2020; 66 (1): 93–103 (in Russ.). https://doi.org/10.14341/probl10333.

17. Lucas T., Astorga R. Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol. 2006; 65 (3): 320–6. https://doi.org/10.1111/j.1365-2265.2006.02595.x.

18. Ilovaiskaya I.A. Current views on the treatment of acromegaly with somatostatin analogues. Meditsinskiy sovet / Medical Council. 2017; 3: 75–9 (in Russ.). https://doi.org/10.21518/2079-701X-2017-3-75-79.

19. Kings Research. Somatostatin analogues market size, share, growth and industry analysis, by type (octreotide, lanreotide and pasireotide), by type (acromegaly, neuroendocrine tumors and others), and regional analysis, 2024–2031. URL: https://www.kingsresearch.com/ru/somatostatin-analogs-market-899 (in Russ.) (accessed 15.01.2025).

20. Omelyanovskiy V.V., Avxentyeva M.V., Sura M.V., et al. Methodical recommendations for conducting a comparative clinical and economic evaluation of a medicinal product. Мoscow: Nauka; 2018: 46 pp. (in Russ.).

21. Omelyanovskiy V.V., Avxentyeva M.V., Khachatryan G.R., et al. Methodological recommendations for the use of mathematical modeling in clinical economic research and research using budget impact analysis. Мoscow: Center for Healthcare Quality Assessment and Control; 2019: 59 pp. (in Russ.).

22. Omelyanovskiy V.V., Avxentyeva M.V., Zheleznyakova I.A., et al. Methodological recommendations for calculating the cost of medical services and cases of medical care provided at the expense of state funding sources. Мoscow: Center for Healthcare Quality Assessment and Control; 2024: 92 pp. (in Russ.).

23. Omelyanovskiy V.V., Avxentyeva M.V., Sura M.V., Ivakhnenko O.I. Methodical recommendations for calculating costs during clinical and economic studies of drugs. Мoscow: Center for Healthcare Quality Assessment and Control; 2017: 24 pp. (in Russ.).

24. Chanson P., Borson-Chazot F., Kuhn J., et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol. 2008; 69 (2): 299–305. https://doi.org/10.1111/j.1365-2265.2008.03208.x.

25. Dreval' A.V., Pokramovich Iu.G., Tishenina R.S. The effectiveness of analysis of octreotide-depo, a long-acting somatostatin analog, for the treatment of the patients presenting with active phase of acromegalia. Problems of Endocrinology. 2014; 60 (3): 10–4 (in Russ.). https://doi.org/10.14341/probl201460310-14.

26. Lutsenko A.S., Przhiyalkovskaya E.G., Vikulova O.K., et al. Russian registry of hypothalamic and pituitary tumors: clinical and statistical analysis for 01.01.2023. Obesity and Metabolism. 2023; 20 (4): 318–29 (in Russ.). https://doi.org/10.14341/omet13054.

27. Hamad A., Rohani Z., Rasul K., et al. EE360 Economic impact of adopting lanreotide for patients with acromegaly and GEP-NET in Qatar. Value in Health. 2024; 27 (12 Suppl.): S125. https://doi.org/10.1016/j.jval.2024.10.641.

28. Alnajjar F., Raef H., Alharbi B., et al. EE168 Budget impact analysis of adopting lanreotide in the treatment of acromegaly and GEP-NET at public hospitals in Saudi Arabia. Value in Health. 2023; 26 (6 Suppl.): S90.

29. Marko N.F., LaSota E., Hamrahian A.H., Weil R.J. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg. 2012; 117 (3): 522–38. https://doi.org/10.3171/2012.4.JNS11739.

30. Marty R., Roze S., Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices. 2012; 5: 39–44. https://doi.org/10.2147/MDER.S30913.

31. Neggers S.J., Pronin V., Balcere I., et al. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015; 173 (3): 313–23. https://doi.org/10.1530/EJE-15-0215.

32. Neggers S., Badiu C., Biagetti B., et al. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly. Expert Rev Clin Pharmacol. 2021; 14 (12): 1551–60. http://doi.org/10. 1080/17512433.2021.1986004.